Centres d'excellences Laboratoires d'excellence

Research Laboratory on Drugs and Therapeutic Innovation

LERMIT

Mots-clés : Médicaments, maladies cardiovasculaires, maladies infectieuses, maladies autoimmunes, cibles thérapeutiques, résistance médicamenteuse, adressage, chimie thérapeutique, galénique, criblage substances naturelles

Résumé

LERMIT is an interdisciplinary consortium composed of 16 laboratories spread over 9 locations within Paris-Saclay, working in biomedicine, chemistry and pharmaceutical sciences. LERMIT’s goal is to explore new therapeutic avenues against cancer, cardiovascular, infectious and immune diseases. LERMIT aims at: 1) better understanding the molecular mechanisms causing these diseases; 2) discovering new therapeutic targets; 3) designing and developing new medications to treat or block the progression of these diseases; 4) developing new strategies for improved targeting and delivery of the medications at the disease site; 5) improving efficacy of current therapeutics.

 

The Research program started in January 2012 with the projects described in the 2010 application. As most of the laboratories had never collaborated before, all these projects were new. In 2015, based on their potential to generate IP, 6 initial projects and 3 new ones were selected for further funding that were pursued until end 2019. In 2018 LERMIT launched a Seed Project Call to reach out to UPSaclay laboratories outside LERMIT to explore possible new research directions, 13 projects were selected. In 2020 the 2nd edition of the Seed Project Call was launched to continue supporting the collaboration between partners and the future Institute of Research on Medication and Innovative Therapeutics, 8 projects were selected. Also to support the research on COVID-19 the LERMIT partner with the UPSaclay and other LabEx for an exceptional research call on this topic, 7 LERMIT projects were funded.

 

The research projects with the support of the LERMIT Maturation and Early Development program have already led to 33 patents families filed from which 12 granted, creation of 3 start-ups and 3,5 M€ cofounding from SATT.

 

The Education program has implemented an annual Summer School, an International Chair of Therapeutic Innovation and an Annual Symposium. 22 PhD fellowships have also been awarded through an annual call.

 

L'auteur de ce résumé est le coordinateur du projet, qui est responsable du contenu de ce résumé. L'ANR décline par conséquent toute responsabilité quant à son contenu.

Informations générales

Acronyme projet : LERMIT
Référence projet : 10-LABX-0033
Région du projet : Île-de-France
Discipline : 5 - Bio Med
Aide PIA : 28 243 243 €
Début projet : avril 2011
Fin projet : décembre 2020

Coordination du projet : Rodolphe FISCHMEISTER
Email : rodolphe.fischmeister@inserm.fr

Consortium du projet

Etablissement coordinateur : Université Paris-Saclay
Partenaire(s) : CEA Saclay, INSERM Paris 13, CNRS IDF Sud (Gif), Ecole Normale Supérieure de Paris-Saclay, Institut Gustave Roussy, CNRS Paris Villejuif, FCS Campus Paris Saclay, AP-HP

Liens utiles

Explorez notre base de projets financés

 

 

L’ANR met à disposition ses jeux de données sur les projets, cliquez ici pour en savoir plus.

Inscrivez-vous à notre newsletter
pour recevoir nos actualités
S'inscrire à notre newsletter